Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
08 August 2023 - 10:30PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that it has advanced the formulation development for its
therapeutic drug, SPC-15. The liquid nasal formulation will be used
in SPC-15’s novel protocol intended for treatment and prevention of
anxiety, PTSD, and other stress related disorders. The formulation
development was in accordance with the Company’s sponsored research
agreement and option with Columbia University. Linearity,
accuracy, and repeatability were achieved in the feasibility study.
“The progress of our feasibility study investigating dose
strengths of SPC-15 is a significant advancement in our development
work with this pipeline candidate,” said Eric Weisblum, Chief
Executive Officer of Silo Pharma. “Results of the feasibility study
will determine our selection of the manufacturing processes, and we
are currently in discussions with potential delivery
partners. We may also use the feasibility data for upcoming
studies related to our SPC-14 therapeutic targeting Alzheimer’s
disease.”
In May 2023, Silo Pharma was awarded a U.S. Patent titled
“Biomarkers for Efficacy of Prophylactic Treatments Against
Stress-Induced Affective Disorders,” with claims protecting the key
technology behind SPC-15 and further drug discovery.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2024 to May 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From May 2023 to May 2024